24 min listen
A MedTech Company That Thinks Like a Biopharma
FromThe Bio Report
ratings:
Length:
34 minutes
Released:
Feb 13, 2020
Format:
Podcast episode
Description
Orchestra BioMed may play at the intersection of drugs and devices, but’s its business strategy is clearly drawn from the biopharmaceutical industry. The company develops its pipeline and then leverages strategic alliances with global partners who can best commercialize its products and maximize their potential. We spoke to David Hochman, CEO of Orchestra BioMed, about the company’s therapeutic devices, the large market opportunities it is targeting, and how it seeks to rewrite the way medtech companies think about partnering.
Released:
Feb 13, 2020
Format:
Podcast episode
Titles in the series (100)
International Collaboration Seeks to Drive Breakthroughs in Progressive MS: There has been dramatic progress in the understanding and treatment of relapsing remitting multiple sclerosis, a debilitating neurodegenerative disorder. But progressive MS, a more advanced form of the disease, has remained elusive. Now, a novel coll... by The Bio Report